Old Web
English
Sign In
Acemap
>
authorDetail
>
Konstanze Diefenbach
Konstanze Diefenbach
Bayer
Regorafenib
Medicine
Pharmacology
Pharmacokinetics
Disposition
3
Papers
47
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects
2018
Cancer Chemotherapy and Pharmacology
Michael Gerisch
Frank-Thorsten Hafner
Dieter Lang
Martin Radtke
Konstanze Diefenbach
Adriaan Cleton
John Lettieri
Show All
Source
Cite
Save
Citations (24)
A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer
2015
Cancer Chemotherapy and Pharmacology
Robin L. Jones
Johanna C. Bendell
David C. Smith
Konstanze Diefenbach
John Lettieri
Oliver Boix
A. Craig Lockhart
Cindy L. O'Bryant
Kathleen N. Moore
Show All
Source
Cite
Save
Citations (16)
Continuous-dose regorafenib (REG) in hepatocellular carcinoma (HCC): Phase I safety and pharmacokinetic (PK) study.
2013
Journal of Clinical Oncology
Richard S. Finn
George R. Blumenschein
Anthony W. Tolcher
Stephen Leong
Oliver Boix
Konstanze Diefenbach
Show All
Source
Cite
Save
Citations (7)
1